The BioHub - by Avetix

In this episode of The BioHub, I’m joined by Dr. Adam Mendelsohn, Co-Founder and CEO of Vivani Medical. Adam’s journey spans bioengineering at UCSF and UC Berkeley to founding Nano Precision Medical and now leading Vivani following its 2022 merger. Vivani is developing long-term, sub-dermal drug implants designed to transform treatment for chronic diseases such as obesity and diabetes. We discuss...

🎙 New Episode Live – Todd Zavodnick, CEO of Excellergy Todd Zavodnick is the CEO of Excellergy , a clinical-stage biotechnology company redefining allergy treatment. Their mission? To make therapies faster, more effective, and far more convenient for patients — transforming the experience of managing allergies. Before Excellergy, Todd built a track record of leadership in biotech, bringing togethe...

Today’s guest is Terry J. Rosen , a scientist-entrepreneur who has helped shape the modern era of cancer immunotherapy. Dr. Rosen is the co-founder and CEO of Arcus Biosciences , a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapies and combination treatments designed to transform outcomes for patients with cancer. Before launching Arcus, he co-founded F...

In this episode of The BioHub, I’m joined by Thijs Spoor, CEO of Perspective Therapeutics. Thijs has taken an unconventional path to the CEO seat, bringing decades of leadership experience across healthcare and capital markets into one of the most exciting areas of biotech: targeted radiopharmaceuticals. We talk about his journey into the industry, the science and vision behind Perspective, the co...

Prior to JPM 2026 and the news of their recent CSL collaboration, I spoke to Memo Therapeutics' CEO, Erik van den Berg for an episode of The BioHub Podcast. Memo are preparing for a global ph3 trial of Potravitug, their antibody against BK polyomavirus infection in kidney transplant recipients. BKPyV infection can lead to nephropathy, loss of kidney function, as well as organ failure, rejectio...

We were delighted to welcome Declan Doogan, CEO of Causeway Therapeutics, onto The BioHub! Declan is a highly respected leader in the biopharmaceutical industry, with decades of experience spanning drug development, clinical research, and executive leadership at some of the world’s leading pharmaceutical companies. Throughout his career, he has played a pivotal role in advancing innovative therapi...

In this episode of The BioHub, I’m joined by Raj Devraj, CEO of Rectify Pharma and Venture Partner at Atlas Venture. Raj has spent his career building biotech companies around bold science, including co-founding Disarm Therapeutics, which was acquired by Eli Lilly. Now he’s doing it again with Rectify. We talk about starting companies from zero, building the right teams early, de-risking new ventu...

We were delighted to Welcome Jim Jenson, CEO of Morphoecueticals a TechBio company focused on understanding and manipulating the bioelectrome to induce regeneration and treat disease.

We were delighted to welcome Simeon George, the CEO and Managing Partner of SR One Capital Management, a global biotech venture capital firm he helped spin out of GSK, onto the BioHub! He’s a physician by training, with an MD from the University of Pennsylvania, an MBA from Wharton, and a background that also includes time at Bain & Company and Goldman Sachs. Over the years, Simeon has helped...

We're joined by Martijn for an engaging discussion on VarmX's latest milestones & the wider biotech market. In Q4 2025, VarmX signed a strategic collaboration with CSL to fully fund a global ph3 trial & pre-launch readiness for their lead asset VMX-C001 - a novel treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while o...

Today’s guest is Kim Hazen, a seasoned people and culture leader with more than two decades of experience shaping organizations at the intersection of science, business, and talent. Kim is currently the Chief People Officer at Fulcrum Therapeutics, where she leads human resources and culture for a clinical-stage biotech company focused on developing treatments for rare genetic diseases. Over the c...

In this episode of The BioHub, I’m joined by Rodolphe Clerval, CEO of Coave Therapeutics. Rodolphe’s journey into the CEO seat wasn’t a traditional one. He moved from science into investment banking, then into major business development roles, before stepping into leadership at multiple biotech companies. We talk about that unconventional path, the story behind Coave’s evolution and rebrand, and w...

We were delighted to be joined by Kevin Pojasek who's the President and CEO of Enara Bio. Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. There pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted ge...

JPM Special — Maureen Hillenmeyer, CEO & Founder of Hexagon Bio In this JPM Special episode of The BioHub, I’m joined by Maureen Hillenmeyer , CEO and Founder of Hexagon Bio. Maureen has built Hexagon around a bold idea: using genomics, computation, and the biology of natural products to unlock entirely new medicines. At JPM, we sat down to talk about what it really takes to build a platform c...

I’m here with Mike Exton, the CEO of LexiconPharmaceuticals. Mike joined Lexicon in 2024 after two decades of leadershipacross Novartis and Eli Lilly, where he helped launch some of the biggest cardiovascular drugs in the world — including Entresto. Now he’s leading Lexicon through a bold new chapter, with agenomics-driven pipeline focused on cardiometabolism and neuroscience, and a strategy built...

In our first JPM Special 2026, we’re joined by Dirk Thye , CEO of Quince Therapeutics , as the company approaches a defining Phase 3 readout. A candid conversation about high-stakes data, leadership under pressure, and what a true do-or-die moment looks like in biotech.

Today’s guest is Kevin Marks, a biotech entrepreneur and the founder and CEO of Delphia Therapeutics. Kevin has spent his career at the forefront of cancer drug discovery, working across research, strategy, and company building with a singular focus on translating breakthrough science into meaningful medicines for patients. Before founding Delphia, he built deep experience in oncology and precisio...

On this episode we're joined by Invivo Partners' Gemma Guinart, for a discussion into early-stage biotech investing. Invivo Partners look to invest in compelling in-vivo proof of concept data, and back founding teams across Europe with pre-seed to Series A investment - recent investments from their third fund include Neumirna Tx & Signadori Bio. Tune in to hear more about how Gemma &am...

We're joined by Ahmet Tutuncu, CEO of AeroRx Therapeutics, to discuss their novel, best-in-class nebulized combination product for moderate-to-severe COPD patients. AeroRx's pipeline includes AERO-007, the first nebulized LABA/LAMA combination in clinical development, and AERO-111, the first triple LABA/LAMA/ICS nebulized therapy in IND-enabling studies. Ahmet previously co-founded Elevati...

On this episode we feature the CEO of Resolution Therapeutics, Amir Hefni. Throughout his career, Amir has held roles with global powerhouses such as BMS, Ipsen, & Novartis, before transitioning to small biotech with Resolution in 2023. Resolution's pipeline of regenerative macrophage therapies originates from research out of Edinburgh University. With potential across inflammatory & fibro...

Today’s guest is Justin To, a leader at the forefront of biotech innovation and gene therapy. Justin currently serves as CEO of QED Therapeutics, a BridgeBio company, where he helps guide the development of treatments for rare genetic diseases. With a background that spans strategy consulting at McKinsey, healthcare technology at Flatiron Health, and multiple leadership roles at BridgeBio, Justin...

We recently sat down with Miquel Vila-Perello, CEO of SpliceBio, at Jefferies - during which the team picked up the Series B Raise of the Year at the 2025 ELAs for their $135million round earlier this year. SpliceBio are a Barcelona-based gene therapy company using a proprietary Protein Splicing platform to address diseases caused by large genes that traditional AAV vectors can’t deliver. Their le...

We were delighted to be joined by Jason Cole, a seasonedbiotechnology executive and the CEO of Zag Bio , a Cambridge-based biotech company taking a novel approach to autoimmune disease, onto The BioHub! Jason brings more than two decades of leadership experience across the biotech industry, spanning company formation, drug development, corporate strategy, and commercialization. Before joining Zag...

Today on The BioHub, I’m joined by Brendan Teehan, Chief Commercial Officer at Pacira BioSciences. Brendan has spent three decades building and leading commercial teams across biopharma, from Johnson & Johnson to Amgen, Tesaro, and Acadia. Now at Pacira, he’s driving the company’s mission to transform pain management through innovative non-opioid therapies. In this conversation, we get into wh...

We recently spoke to Lance Baldo, CEO of Beacon Therapeutics, during the Jefferies Healthcare Conference.  Beacon's Vista ph3 trial for laru-zova, their AAV Gene Therapy for X-Linked Retinitis Pigmentosa, has completed enrolment with topline expected in mid-2026. Listen in to hear about Lance's career, from roles with Roche in both Switzerland & New Zealand to a return to the US with G...